Symbols / ALZN Stock $1.13 +2.73% Alzamend Neuro, Inc.

Healthcare • Biotechnology • United States • NCM
ALZN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Stock Fundamentals
Scroll to Statements
Market Cap 4.30M Enterprise Value 1.59M Income -7.54M Sales — Book/sh 0.57 Cash/sh 0.71
Dividend Yield — Payout 0.00% Employees 4 IPO — P/E — Forward P/E -0.43
PEG — P/S — P/B 1.97 P/C — EV/EBITDA -0.23 EV/Sales —
Quick Ratio 1.46 Current Ratio 1.99 Debt/Eq — LT Debt/Eq — EPS (ttm) -3.67 EPS next Y -2.60
EPS Growth — Revenue Growth — Earnings 2026-03-11 ROA -107.01% ROE -249.97% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 3.80M Shs Float 3.79M Short Float 8.62%
Short Ratio 1.33 Short Interest — 52W High 8.22 52W Low 0.84 Beta -0.05 Avg Volume 140.61K
Volume 65.06K Target Price $25.00 Recom None Prev Close $1.10 Price $1.13 Change 2.73%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.00
Mean price target
2. Current target
$1.13
Latest analyst target
3. DCF / Fair value
$-17.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.13
Low
$25.00
High
$25.00
Mean
$25.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-22 main Ascendiant Capital Buy → Buy $28
2025-09-25 main Ascendiant Capital Buy → Buy $42
2025-08-21 main Ascendiant Capital Buy → Buy $45
2025-03-17 main Ascendiant Capital Buy → Buy $20
2024-12-16 main Ascendiant Capital Buy → Buy $32
2024-11-11 main Ascendiant Capital Buy → Buy $35
News
RSS: Latest ALZN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-14 AULT MILTON C III Director — 108,388 $1.00 $108,897
2025-12-23 AULT MILTON C III Director — 1,851 $2.07 $3,825
2025-12-19 HORNE WILLIAM B Director — 3,333 $2.12 $7,059
2025-10-23 MCGRATH LYNNE FAHEY Director — 30 $2.29 $69
2025-10-09 AULT MILTON C III Director — 121,791 $2.32 $294,548
2025-10-08 AULT MILTON C III Director — 61,743 $2.32 $143,244
2025-10-07 AULT MILTON C III Director — 139,412 $2.45 $344,222
2025-10-07 AULT MILTON C III Director — 200,000 $2.32 $464,000
2025-10-03 AULT MILTON C III Director — 123,366 $2.35 $296,789
2025-10-01 AULT MILTON C III Director — 100,000 $2.32 $232,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
4.50
-54.75%
9.94
-33.17%
14.87
+20.71%
12.32
Research And Development
1.41
-78.08%
6.46
-13.31%
7.45
+43.15%
5.20
Selling General And Administration
3.08
-11.50%
3.48
-53.09%
7.42
+4.30%
7.12
Selling And Marketing Expense
0.35
+40.42%
0.25
-66.69%
0.74
+4106.42%
0.02
General And Administrative Expense
2.73
-15.47%
3.24
-51.58%
6.68
-5.89%
7.10
Salaries And Wages
1.51
-12.99%
1.74
-63.97%
4.82
-6.64%
5.16
Other Gand A
0.96
-13.67%
1.12
-12.47%
1.28
+4.14%
1.23
Total Expenses
4.50
-54.75%
9.94
-33.17%
14.87
+20.71%
12.32
Operating Income
-4.50
+54.75%
-9.94
+33.17%
-14.87
-20.71%
-12.32
Total Operating Income As Reported
-4.50
+54.75%
-9.94
+33.17%
-14.87
-20.71%
-12.32
EBITDA
-4.45
+55.03%
-9.89
+33.41%
-14.85
-20.59%
-12.31
Normalized EBITDA
-4.45
+55.03%
-9.89
+33.41%
-14.85
-20.55%
-12.32
Reconciled Depreciation
0.05
+0.00%
0.05
+119.98%
0.02
+549.93%
0.00
EBIT
-4.50
+54.75%
-9.94
+33.17%
-14.87
-20.75%
-12.32
Total Unusual Items
—
—
0.00
-100.00%
0.00
Total Unusual Items Excluding Goodwill
—
—
0.00
-100.00%
0.00
Special Income Charges
—
—
0.00
-100.00%
0.00
Other Special Charges
—
—
—
-0.00
Net Income
-4.51
+54.61%
-9.95
+33.14%
-14.88
-20.35%
-12.36
Pretax Income
-4.51
+54.61%
-9.95
+33.14%
-14.88
-20.35%
-12.36
Net Non Operating Interest Income Expense
-0.02
-78.49%
-0.01
-31.16%
-0.01
+83.45%
-0.05
Interest Expense Non Operating
0.02
+78.49%
0.01
+31.16%
0.01
-83.45%
0.05
Net Interest Income
-0.02
-78.49%
-0.01
-31.16%
-0.01
+83.45%
-0.05
Interest Expense
0.02
+78.49%
0.01
+31.16%
0.01
-83.45%
0.05
Interest Income Non Operating
—
—
—
0.00
Interest Income
—
—
—
0.00
Other Income Expense
—
—
—
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-4.51
+54.61%
-9.95
+33.14%
-14.88
-20.35%
-12.36
Net Income From Continuing Operation Net Minority Interest
-4.51
+54.61%
-9.95
+33.14%
-14.88
-20.35%
-12.36
Net Income From Continuing And Discontinued Operation
-4.51
+54.61%
-9.95
+33.14%
-14.88
-20.35%
-12.36
Net Income Continuous Operations
-4.51
+54.61%
-9.95
+33.14%
-14.88
-20.35%
-12.36
Normalized Income
-4.51
+54.61%
-9.95
+33.14%
-14.88
-20.31%
-12.37
Net Income Common Stockholders
-5.11
+48.68%
-9.95
+33.14%
-14.88
-20.35%
-12.36
Diluted EPS
-11.32
+91.45%
-132.33
+42.19%
-228.90
-21.11%
-189.00
Basic EPS
-11.32
+91.45%
-132.33
+42.19%
-228.90
-21.11%
-189.00
Basic Average Shares
0.45
+499.67%
0.08
+15.63%
0.07
-1.49%
0.07
Diluted Average Shares
0.45
+499.67%
0.08
+15.63%
0.07
-1.49%
0.07
Diluted NI Availto Com Stockholders
-5.11
+48.68%
-9.95
+33.14%
-14.88
-20.35%
-12.36
Insurance And Claims
0.26
-32.05%
0.38
-35.02%
0.59
-17.77%
0.71
Preferred Stock Dividends
0.59
—
—
—
Line Item Trend 2024-04-30
Total Assets
0.63
Current Assets
0.46
Cash Cash Equivalents And Short Term Investments
0.38
Cash And Cash Equivalents
0.38
Cash Financial
0.38
Receivables
—
Other Receivables
—
Accrued Interest Receivable
—
Prepaid Assets
0.08
Current Deferred Assets
—
Total Non Current Assets
0.18
Net PPE
0.18
Total Liabilities Net Minority Interest
3.23
Current Liabilities
3.23
Payables And Accrued Expenses
2.93
Payables
2.93
Accounts Payable
2.93
Current Debt And Capital Lease Obligation
0.30
Current Debt
0.30
Other Current Borrowings
—
Total Non Current Liabilities Net Minority Interest
0.00
Stockholders Equity
-2.59
Common Stock Equity
-2.59
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.08
Ordinary Shares Number
0.08
Treasury Shares Number
0.00
Additional Paid In Capital
51.43
Retained Earnings
-54.02
Total Equity Gross Minority Interest
-2.59
Total Capitalization
-2.59
Working Capital
-2.77
Invested Capital
-2.29
Total Debt
0.30
Net Tangible Assets
-2.59
Tangible Book Value
-2.59
Current Notes Payable
0.30
Dueto Related Parties Current
—
Notes Receivable
—
Other Equity Interest
—
Preferred Stock Equity
—
Line Item Trend 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Operating Cash Flow
-6.57
+20.58%
-8.27
+7.32%
-8.92
-34.91%
-6.61
Cash Flow From Continuing Operating Activities
-6.57
+20.58%
-8.27
+7.32%
-8.92
-34.91%
-6.61
Net Income From Continuing Operations
-4.51
+54.61%
-9.95
+33.14%
-14.88
-20.35%
-12.36
Depreciation Amortization Depletion
0.05
+0.00%
0.05
+119.98%
0.02
+549.93%
0.00
Depreciation
0.05
+0.00%
0.05
+119.98%
0.02
+549.93%
0.00
Depreciation And Amortization
0.05
+0.00%
0.05
+119.98%
0.02
+549.93%
0.00
Other Non Cash Items
0.01
+1200.56%
0.00
—
0.01
Stock Based Compensation
0.33
-65.98%
0.96
-73.33%
3.58
-18.73%
4.41
Operating Gains Losses
—
—
—
-0.00
Change In Working Capital
-2.44
-463.59%
0.67
-71.45%
2.35
+77.02%
1.33
Change In Prepaid Assets
-0.15
-124.28%
0.62
-4.10%
0.64
+1.33%
0.63
Change In Payables And Accrued Expense
-2.29
-4266.49%
0.05
-96.78%
1.71
+146.15%
0.69
Investing Cash Flow
-0.30
-103.74%
-0.15
0.00
+100.00%
-0.11
Cash Flow From Continuing Investing Activities
-0.30
-103.74%
-0.15
0.00
+100.00%
-0.11
Net PPE Purchase And Sale
-0.30
-103.74%
-0.15
0.00
+100.00%
-0.11
Purchase Of PPE
-0.30
-103.74%
-0.15
0.00
+100.00%
-0.11
Capital Expenditure
-0.30
-103.74%
-0.15
—
-0.11
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
10.44
+185.86%
3.65
+1826112.50%
0.00
-100.00%
18.85
Cash Flow From Continuing Financing Activities
10.44
+185.86%
3.65
+1826112.50%
0.00
-100.00%
18.85
Net Issuance Payments Of Debt
0.00
-100.00%
0.30
0.00
+100.00%
-0.06
Issuance Of Debt
0.00
-100.00%
0.30
0.00
0.00
Repayment Of Debt
—
—
0.00
+100.00%
-0.06
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
0.00
+100.00%
-0.06
Net Long Term Debt Issuance
—
—
0.00
+100.00%
-0.06
Short Term Debt Issuance
0.00
-100.00%
0.30
0.00
—
Net Short Term Debt Issuance
0.00
-100.00%
0.30
0.00
—
Net Common Stock Issuance
2.70
+115.91%
1.25
0.00
-100.00%
18.91
Proceeds From Stock Option Exercised
0.00
0.00
-100.00%
0.00
-90.91%
0.00
Net Other Financing Charges
—
—
—
—
Changes In Cash
3.57
+174.98%
-4.76
+46.60%
-8.92
-173.53%
12.13
Beginning Cash Position
0.38
-92.69%
5.14
-63.45%
14.06
+628.97%
1.93
End Cash Position
3.95
+950.04%
0.38
-92.69%
5.14
-63.45%
14.06
Free Cash Flow
-6.87
+18.40%
-8.42
+5.67%
-8.92
-32.78%
-6.72
Common Stock Issuance
2.70
+115.91%
1.25
0.00
-100.00%
18.91
Issuance Of Capital Stock
10.44
+211.42%
3.35
0.00
-100.00%
18.91
Net Preferred Stock Issuance
7.74
+268.39%
2.10
0.00
—
Preferred Stock Issuance
7.74
+268.39%
2.10
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category